FDA Misses PDUFA Date for Liquidia’s NDA for Inhaled Blood Pressure Drug

Submitted by admin on January 25, 2024 - 9:01pm

Source:

BioSpace

News Tags:

Liquidia

FDA

Yutrepia

hypertension

Headline:

FDA Misses PDUFA Date for Liquidia’s NDA for Inhaled Blood Pressure Drug

snippet:

Liquidia remains stuck in regulatory limbo as the FDA extended its review period for Yutrepia’s New Drug Application. The company announced Thursday in an update that the regulator missed its Jan. 24 PDUFA goal date and the agency’s review remains ongoing.

Search form

You are here

FDA Misses PDUFA Date for Liquidia’s NDA for Inhaled Blood Pressure Drug

FDA Misses PDUFA Date for Liquidia’s NDA for Inhaled Blood Pressure Drug